Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatChemical/toxinWistarMalen = Five groups of six animals each, 30 in total; acute toxicit…Oral gavage; toxicant intraperitoneal150 and 300 mg/kg; silymarin comparator 50 mg/kg orally in…Prophylactic pre-treatment for 14 days before injury induction on day 15
Model: Fulminant hepatic failure induced by D-galactosamine 400 mg/kg with lipopolysaccharide 30 micrograms/kg intraperitoneally on day 15, with sampling 24 hours later
Pre-treatment dose-dependently lowered liver enzymes, lipid peroxidation, myeloperoxidase, NF-kappaB activity and pro-inflammatory and apoptotic markers while raising antioxidant enzymes, IL-10 and Bcl-2, with histology comparable to silymarin.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.